15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 精华资料 存档 1 我们的希望在这里……-->特深沉转移
楼主: L.H

我们的希望在这里……-->特深沉转移 [复制链接]

Rank: 4

现金
794 元 
精华
帖子
339 
注册时间
2002-9-18 
最后登录
2007-7-6 
61
发表于 2002-10-31 10:52
希望总是有的
现在养好身体啊
好好对自己
凉风有信,秋月无边,我那思娇的情绪,好比度日如年。。。。。。。。。。。

Rank: 4

现金
187 元 
精华
帖子
86 
注册时间
2002-12-13 
最后登录
2009-6-3 
62
发表于 2002-12-15 05:05
老兄!这些新药对于我们来说只是望梅止渴而已。对于已经肝硬化的病人恐怕能等到那一天了。呜~~~~~呜。
换个零件继续颠~!2008年11月19日是咱的第二次生命的开始~!

Rank: 4

现金
612 元 
精华
帖子
409 
注册时间
2002-10-5 
最后登录
2006-10-10 
63
发表于 2002-12-25 07:55
好消息rnai明年进入临床试验,见12.23.7版《参拷消息》

Rank: 4

现金
612 元 
精华
帖子
409 
注册时间
2002-10-5 
最后登录
2006-10-10 
64
发表于 2002-12-25 07:56
好消息rnai明年进入临床试验,见12.23.7版《参拷消息》

Rank: 4

现金
248 元 
精华
帖子
155 
注册时间
2002-12-28 
最后登录
2004-7-31 
65
发表于 2002-12-28 22:19
如果我们的政府,把这十分之一的人,当作是一形象工程,解决了这个问题,等于解决了国家的根本问题,中国共产党就是世界上最伟大的党。

Rank: 4

现金
391 元 
精华
帖子
98 
注册时间
2002-12-17 
最后登录
2017-11-15 
66
发表于 2002-12-29 02:28
是啊,把这十分之一的人,解决了问题,谁就是获得诺贝尔奖!

Rank: 4

现金
125 元 
精华
帖子
53 
注册时间
2002-9-26 
最后登录
2005-9-17 
67
发表于 2002-12-31 01:17
BREAKTHROUGH OF THE YEAR:
Small RNAs Make Big Splash
Jennifer Couzin

#1 The Winner

Just when scientists thought they had deciphered the roles played by the cell's leading actors, a familiar performer has turned up in a stunning variety of guises. RNA, long upstaged by its more glamorous sibling, DNA, is turning out to have star qualities of its own.
See
Web links
on RNA  
For decades, RNA molecules were dismissed as little more than drones, taking orders from DNA and converting genetic information into proteins. But a string of recent discoveries indicates that a class of RNA molecules called small RNAs operate many of the cell's controls. They can turn the tables on DNA, shutting down genes or altering their levels of expression. Remarkably, in some species, truncated RNA molecules literally shape genomes, carving out chunks to keep and discarding others. There are even hints that certain small RNAs might help chart a cell's destiny by directing genes to turn on or off during development, which could have profound implications for coaxing cells to form one type of tissue or another. Science hails these electrifying discoveries, which are prompting biologists to overhaul their vision of the cell and its evolution, as 2002's Breakthrough of the Year.



--------------------------------------------------------------------------------

Life cycle. With a helping hand from proteins RISC and Dicer, small RNAs are born. We now know that these molecules keep DNA in line and ensure a cell's good health.
ILLUSTRATION: C. SLAYDEN/G. RIDDIHOUGH



--------------------------------------------------------------------------------

These astonishing feats are performed by short stretches of RNA ranging in length from 21 to 28 nucleotides. Their role had gone unnoticed until recently, in part because researchers, focused on the familiar larger RNA molecules, tossed out the crucial small ones during experiments. As a result, RNA has long been viewed primarily as an essential but rather dull molecule that ferries the genetic code from the nucleus to the ribosomes, the cell's protein factories, and helps assemble amino acids in the correct order during protein synthesis.

Signs that RNA might be more versatile came in the early 1990s, when biologists determined that some small RNAs could quash the expression of various genes in plant and, later, animal cells. But they didn't appreciate the molecules' true powers until 1998. That's when Andrew Fire of the Carnegie Institution of Washington in Baltimore, Maryland, Craig Mello of the University of Massachusetts Medical School in Worcester, and their colleagues injected stretches of double-stranded RNA into worms. Double-stranded RNA forms when a familiar single strand kinks back in a hairpin bend, putting two complementary sequences alongside each other. To the researchers' surprise, double-stranded RNA dramatically inhibited genes that had helped generate the RNA in the first place. This inhibition, which was later seen in flies and other organisms, came to be known as RNA interference (RNAi). It helped prove that RNA molecules were behind some gene silencing.

Another crucial step came last year, when Gregory Hannon of Cold Spring Harbor Laboratory in New York and his colleagues identified an enzyme, appropriately dubbed Dicer, that generates the small RNA molecules by chopping double-stranded RNA into little pieces. These bits belong to one of two small RNA classes produced by different types of genes: microRNAs (miRNAs) and small interfering RNAs (siRNAs). SiRNAs are considered to be the main players in RNAi, although miRNAs, which inhibit translation of RNA into protein, were recently implicated in this machinery as well.

To bring about RNAi, small RNAs degrade the messenger RNA that transports a DNA sequence to the ribosome. Exactly how this degradation occurs isn't known, but scientists believe that Dicer delivers small RNAs to an enzyme complex called RISC, which uses the sequence in the small RNAs to identify and degrade messenger RNAs with a complementary sequence.

Such degradation ratchets down the expression of the gene into a protein. Although quashing expression might not sound particularly useful, biologists now believe that in plants, RNAi acts like a genome "immune system," protecting against harmful DNA or viruses that could disrupt the genome. Similar hints were unearthed in animals this year. In labs studying gene function, RNAi is now commonly used in place of gene "knockouts": Rather than delete a gene, a laborious process, double-stranded RNA is applied to ramp down its expression.

The year's most stunning revelations emerged in the fall, in four papers examining how RNA interference helps pilot a peculiar--and pervasive--genetic phenomenon known as epigenetics. Epigenetics refers to changes in gene expression that persist across at least one generation but are not caused by changes in the DNA code.

In recent years, researchers have found that one type of epigenetic regulation is caused by adjustments in the shape of complexes known as chromatin, the bundles of DNA and certain fundamental proteins that make up the chromosomes. By changing shape--becoming either more or less compact--chromatin can alter which genes are expressed. But what prompts this shape-shifting remained mysterious.

This year, scientists peering closely at RNAi in two different organisms were startled to find that small RNAs responsible for RNAi wield tremendous control over chromatin's form. In so doing, they can permanently shut down or delete sections of DNA by mechanisms not well understood, rather than just silencing them temporarily.

That news came from several independent groups. In one case, Shiv Grewal, Robert Martienssen, and their colleagues at Cold Spring Harbor Laboratory compared fission yeast cells lacking RNAi machinery with normal cells. When yeast cells divide, their chromosomes untangle and migrate to opposite sides of the cell. The researchers already knew, broadly, that this chapter of cell division is governed by a tightly wrapped bundle of chromatin, called heterochromatin, around the centromere--the DNA region at the chromosome's "waist." The biologists found that their mutant cells, which were missing the usual small RNAs, couldn't properly form heterochromatin at their centromeres and at another DNA region in yeast that controls mating. This suggests that without small RNAs, cell division goes awry. The scientists theorized that in healthy yeast cells, small RNAs elbow their way into cell division, somehow nudging heterochromatin into position to do the job. That exposes DNA to different proteins and dampens gene expression.

Meanwhile, David Allis and his colleagues at the University of Virginia Health System in Charlottesville, along with Martin Gorovsky of the University of Rochester in New York and others, were focusing on a different organism, a single-celled ciliate called Tetrahymena. Biologists treasure Tetrahymena because it stores the DNA passed to offspring in a different nucleus from the one containing DNA expressed during its lifetime, making it easy to distinguish one gene set from the other. The researchers found that in Tetrahymena, small RNAs trigger deletion or reshuffling of some DNA sequences as a cell divides. RNAi appeared to be targeting structures analogous to heterochromatin, only this time strips of DNA were discarded or moved elsewhere. The mechanism remains unclear, however.

The two sets of experiments might help explain why small RNAs exist in the first place. In both the yeast and Tetrahymena, small RNAs' frenetic activity is focused on genome regions, such as centromeres, that contain repetitive DNA resulting from transposons. Transposons are bits of DNA that can jump around the genome and insert themselves at different locales; at times, they jam transcription machinery and cause disease. It appears possible--although still largely hypothetical--that small RNAs evolved very early in life's history to help protect the genome against instability.

This is just one of many areas that remain to be explored. Researchers are still trying to sort out how the well over 100 different miRNAs function and which species contain which ones. There are hints that they behave differently in plants and animals. And some recent work suggests that miRNAs exert more control over gene expression than previously believed. Also a focus of research are the proteins, such as Dicer, that are critical cogs in the RNAi machinery.

Researchers are also probing RNAi's possible role in development and disease. RNAi has been implicated in guiding meristems, the plant version of stem cells, so some biologists believe that it might help establish the path taken by human and other mammalian stem cells as they differentiate into certain tissues. If so, RNAi could prove an essential tool in manipulating stem cells. And if small RNAs influence cell division in humans as they do in yeast and Tetrahymena, minor disruptions in the machinery could lead to cancer.

The extraordinary, although still unfulfilled, promise of small RNAs and RNAi has split the field wide open and put RNA at center stage. Having exposed RNAs' hidden talents, scientists now hope to put them to work.

Rank: 4

现金
125 元 
精华
帖子
53 
注册时间
2002-9-26 
最后登录
2005-9-17 
68
发表于 2002-12-31 01:21
From cancer to Aids: the RNAi revolution is gathering pace
By Steve Connor, Science Editor
06 September 2002


Internal links

Gene breakthrough destroys cancer cells

From cancer to Aids: the RNAi revolution is gathering pace

The dramatic results of early experiments using RNA interference (RNAi) ­ showing that it destroys cancer cells in a test tube ­ have raised an important question: will the revolutionary technique work on patients?

Scientists have been astonished by the power of RNAi to neutralise viruses and cancer cells but there has always been a nagging doubt that it might be just another test-tube wonder that fails the clinical test.

With the latest findings showing that RNAi protects human cells against cancer and lethal viruses, attention will be focused on John Rossi, a medical scientist who will soon carry out the world's first clinical trial of the technique.

Dr Rossi, a senior scientist at the Beckman Research Institute at the City of Hope Cancer Centre in Duarte, California, has drawn up preliminary plans to use RNAi on a group of Aids patients having bone-marrow transplants for lymphoma, a type of cancer.

If RNAi works against HIV, there is a good chance it will work against other "incurable" diseases. Success would open new avenues to treating many other lethal viruses, as well as cancer and tissue rejection after transplant surgery.

The research published yesterday by a team from the University of York focused on cervical cancer cells.

Professor Jo Milner's team targeted the RNAi against two of the genes of the human papilloma virus. By silencing one gene, the tumour cells stopped growing. By silencing the other gene, all the cancer cells committed "suicide".

Because the treatment had no effect on uninfected human cells, this is strong evidence that RNAi would be unlikely to produce the harmful side-effects seen with other cancer treatments. Professor Milner said that she intended to start clinical trials for cervical cancer treatment within five years. Cervical cancer kills some 1,250 British women each year.

The world's first clinical trial with RNAi, however, is likely to take place on Aids patients in the US. Dr Rossi said that he already had Aids patients receiving a similar treatment that could be adapted to incorporate RNAi.

"We envision within a year, or two at the most, that we'll be able to do the first RNAi testing in patients because we have the infrastructure already laid for this kind of therapeutic approach," Dr Rossi said.

RNAi has become the hottest topic in biology and has already proved itself as an extraordinarily powerful research tool ­ geneticists say it will revolutionise the study of the human genome.

RNAi works by "silencing" any chosen gene. Scientists have shown it can be used to turn off the harmful genes of infectious viruses or malignant tumour cells.

Dr Rossi's trial will be a critical first test of RNAi in a practical setting. A trial is imperative, he said, because of the incredibly persuasive evidence that RNAi works against HIV.

When they applied the approach to human cells growing in a test tube, they could hardly believe their eyes when the cells became 10,000 times better at resisting attack by HIV. "Normally when we do this sort of experiment we are lucky if we get 90 per cent inhibition with even the best things we put in," he said.

"This time we got the most substantial inhibition we've ever seen with any gene therapy approach."

His research institute, 26 miles north-east of Los Angeles, will need ethical approval from US regulators. But first Dr Rossi will have to conduct a series of safety experiments on animals, which will be paid for by the government's National Institutes of Health. The trial will involve extracting stem cells from patients' bone marrow and genetically engineering them with synthetic genes that cause the cells to produce short, double-stranded molecules of RNA, a close relation of DNA.

These RNA molecules are known to interfere with the way other genes work and they can be specifically made to target harmful genes, such as those that are vital for HIV or a tumour cell to replicate.

In theory RNAi should be safe because not only is it a natural process for silencing genes, but it can be made to be specific to genes carried solely by viruses or cancer cells.

However, Dr Rossi said that ethical committees would demand extensive safety data from the animal studies before allowing the technique to be used on patients. "This will definitely turn out to be very powerful. The only question is safety," he said.

The animal studies will have to show that genetically engineered stem cells honed by RNAi to silence certain critical genes of the Aids virus are themselves not altered by the process. In particular the scientists will have to show that the stem cells can still go on to differentiate into healthy blood cells in the normal way.

Phillip Sharp, a Nobel laureate who is working on RNAi at the Massachusetts Institute of Technology, has also shown that the technique can suppress HIV in human cells. However, the Rossi group did it by genetic engineering rather than adding short segments of double-stranded RNA to cells.

"We actually engineer the cells to produce RNAi that's targeted to HIV and we showed we can get remarkable protection, but that was in a short-term experiment," he said.

"We were one of the first groups to report that you can express short RNAs in human cells and get them to knock out HIV," he added. "So instead of putting it in from the outside, like the Phil Sharp group, we expressed them from the inside of the cells."

Dr Sharp has set up a company called Alnylam ­ which is Arabic for "string of pearls" ­ to develop RNAi using $17m (£12m) of venture capital. He too has little doubt about its potential. "This is really exciting and it's captured the imagination of just about the total worldwide biological community. This is the broadest, most general advance that I have known of for a long period."

Dr Sharp has become one of RNAi's most fervent admirers. "It's one of the more interesting and exciting developments over the last decade," he said.

"We didn't have before this a general method of turning genes off. Now there is a method that can turn genes off by your design, not the cell's design. I think that's a very important, general concept."

Sir Paul Nurse, another Nobel laureate and the director general of Cancer Research UK, said that RNAi offered great potential but he stressed that the research was still at an early stage.

"When we come to therapy it's very much more difficult to know how much more effective it's going to be. There is clear promise but I think it's still a bit early to know," Sir Paul said.

"In terms of a method for treating disease, it has clear potential but I think we have to see how it works out. The real difficulty is delivering these agents adequately and appropriately," he said.

"I'm sure you can think about clinical trials and I'm sure they will happen, and indeed should happen, if they are shown to be safe and promising but we shouldn't think that this is absolutely the panacea we've been looking for. It might be absolutely fantastic or it might not turn out to be as easy as we think."

Dr Sharp, meanwhile, is hoping that Dr Rossi's clinical trial works out as intended. "It would be exciting if he could do it. I wish him luck."

All in the genes: discovery of RNAi

The discovery of RNA interference (RNAi) goes back more than 10 years to experiments on petunia plants but the name was coined in 1998 when scientists showed that the technique of gene "silencing" applied to nematode worms. Earlier this year scientists demonstrated that RNAi worked on mammalian cells, including those of humans.

Ribonucleic acid (RNA) is closely related to DNA, the molecule of inheritance, and it performs various functions, including acting as a "messenger" by carrying genetic instructions from the chromosomes of the cell's nucleus to the protein factories of the cell's cytoplasm, the region outside the nucleus.

Scientists have been astonished to find that there is a type of double-stranded RNA that selectively blocks these messages, thus "silencing" a gene on a chromosome without actually interfering with the DNA of the gene directly. They called this RNA interference.

RNAi may actually be a very ancient form of defence against viruses, which is shared by all multi-celled organisms, from yeast to man. If doctors could tap into this defensive mechanism, a radically different approach would be opened up to dealing with viruses, which are notoriously difficult to treat with conventional drugs.

Test-tube experiments showed that RNAi could be used to make human cells growing in a test tube immune to infection with polio virus and HIV. And now Professor Jo Milner at York University has demonstrated the ability of RNAi to kill cervical cancer cells by silencing the genes of the human papilloma virus.

Scientists are excited by RNAi because it can be designed to attack specific genes so accurately. Because all viruses possess genes that are unique, the selectivity means an RNAi treatment should only affect the virus in question.

The early, test-tube experiments appear to support this. Professor Milner's study showed that RNAi had no discernible effect on healthy cells.

For a test-tube technique to cause so much interest among cancer and Aids specialists is unusual. They will be monitoring the first clinical trials closely to see if this excitement is justified.
   26 December 2002 22:04

Search this site:
  

Printable Story

Rank: 4

现金
612 元 
精华
帖子
409 
注册时间
2002-10-5 
最后登录
2006-10-10 
69
发表于 2002-12-31 07:20
那位老兄译出来啊,

Rank: 4

现金
125 元 
精华
帖子
53 
注册时间
2002-9-26 
最后登录
2005-9-17 
70
发表于 2003-1-1 00:47
RNA 沉默:基因组的免疫系统  
译者语:RNA沉默,的确是在基因组水平的免疫现象,不仅在动物体内存在,而且在植物体内也存在,是一种原始的基因组对抗来自外来基因表达的保护机制。如果我们认为它是属于免疫的范畴,那么传统免疫系统的内容是否应该改写,是否应该有一门叫《基因组免疫学》的分支学科?很值得探讨。


  

  王辉 节译


所有复杂生物的基因组是病毒和转座子入侵潜在的目标。人类基因组45%是由以前的转座子/病毒的遗留部分组成:21%的长散布元件(LINE)、13%的短散布元件(SINE)、8% 的逆转录病毒和3%DNA转座子,比编码蛋白(非转座子)的基因少2% 。人们期望生物体能和这些入侵者战斗,以避免基因组被分子入侵者完全占领。生物体保护基因组的完整性类似于脊椎动物的免疫系统,存在两个问题:1、如何识别"自己"和"非己"和2、怎样以特殊的方式放大起始的应答?

脊椎动物的免疫系统与入侵者战斗采用两步战略:通过基因重排,使有限的基因片段组成很多抗体编码基因 ,各种抗体编码基因分布在大量细胞之中。 感染以后,通过克隆选择和相应细胞的扩增, 产生针对免疫原的特异性免疫应答。脊椎动物的免疫系统,在早期发育阶段通过产生多少不等的任意成分,经过耐受诱导的滤过过程:针对自身抗原的细胞被从成熟的免疫系统中清除,已经解决了特异性的问题。

基因组是如何识别入侵者及对他们产生一个具有压倒性和特异性的"免疫应答"的呢?一种策略是通过在基因组中的转座子序列甲基化来抑制转座子,虽然这种现象是次要的抑制效果,但还在被争论,这里不进一步讨论,已有很多这方面的综述。近年来,一个使RNA沉默的机制在不同的物种(真菌、动物和植物)中被发现,很可能作为基因组的"免疫系统"。在其机制被认识以前,在不同生物体中这个系统开始被独立发现和研究。在植物中转录后基因沉默(Posttranscriptional gene silencing ,PTGS) 和共同抑制、植物中RNA介导的病毒抵抗、动物中的RNA干预(第一个在新小杆线虫属线虫中被发现)、和在真菌及藻中(链孢菌属中的"镇压")的沉默,所有这些都是基于同样的核心机制。这种结论是建立在共同作用因子的发现(小干预RNA,small interfering RNAs ,siRNAs)和在植物、动物、真菌和藻中这种机制所需的基因之间的同源性。

这些现象的真正机制正在迅速被阐明,被认为是RNA沉默。我认为RNA沉默就等于脊椎动物免疫系统产生大规模免疫应答的"克隆选择"。


RNA沉默的功能

正常情况下,线虫和果蝇都不会遇到高浓度的与内源某个基因相同的双链RNA(dsRNA)。然而,遗传分析显示通过外源dsRNA触发基因沉默所需要的基因数量大于10倍。那么这种精细途径的自然功能是什么?

在植物中,从最清晰的照片中可以看到,转录后基因沉默和病毒诱导的基因沉默是针对频繁出现的病毒感染的保护机制。这种防御系统的优势是其防御信号可以扩散,如果接种一片树叶的一个区域,能将免疫力给予周围的细胞。关于这个问题的一项研究显示,一种动物病毒同样编码一个RNA干预(RNAi)的抑制者,支持关于在动物中RNAi可能具有抗病毒功能的概念。在线虫,RNAi所需的基因功能丢失导致胚系多种转座子的激活,证明在蠕虫的后代基因组内RNAi的功能是抑制转座子的扩散。

保护性对抗病毒和转座子可能是RNAi途径的自然功能的核心,但它不能解释RNAi的所有方面的作用。在线虫中,RNAi的最明显的特征之一是它的全身效应,在动物的一个部位注射裸dsRNA可以影响其他部位基因的表达,并且dsRNA和食物一起给予通过肠腔吸收,在性腺中发现影响子代基因的表达。在植物,嫁接实验已经显示免疫力可以在干组织移动超过30厘米;这种能力可以增加保护作用以防被病毒重复感染 。这种全身效应并不是在所有系统都能看到。至于线虫,RNA沉默效应能够被食物中dsRNA触发。 线虫能从食物中摄入核酸前体。通过食物诱导的RNAi 可能利用了两个途径,一个是自然功能,摄入核酸是用于复制和转录,另一个功能是防止病毒和转座子的入侵。


自己和非己

将dsRNA触发的RNAi作为基因组的"免疫系统",人们可能要问:转座子和病毒是如何诱导与它们自己序列相对应的dsRNA 的?在线虫,至少可有三个可能的解释。第一,一旦一个基因单元已经将多个拷贝插入基因组的任意位置,从启动子端开始连续转录可以从两条链产生RNA,形成dsRNA。这种情况出现的机会将随着插入的数量而增加, 这将提供一个感受随机整合的拷贝数的装置,存在于基因组中的一种转座子扩散的感受器。第二, 在线虫中的知道要被RNAi调节的转座子有末端反向重复序列。一个单拷贝的连续阅读转录能够产生与这些末端对应的折回dsRNAR。我们在线虫中确实观察到与转座子末端对应的dsRNA 。 第三,可能存在其他转座子感受器 。所有"好"基因在它们的mRNA中分享结构基序,甚至可能是5' 和 3' 端之间的相互作用,及蛋白质因子与它们的结合。 缺乏这些特征的mRNAs 通过一个特殊的装置转变成dsRNA。转座子沉默有缺陷的几个线虫突变,在给予dsRNA后在RNAi中没有缺陷 ,可能存在将外源mRNAs转变成dsRNA的步骤。

在转基因沉默中有缺陷的植物突变,在病毒诱导沉默中没有发现缺陷。它们包含一个RNA-引导的RNA聚合酶(RdRP)的突变,它的可能作用是将外源转基因的单链RNA(ssRNA)变成dsRNA。这样,对于病毒这个非己成分能简单的生成dsRNA,而对转基因这个非己成分,则需要RdRP 识别然后将单链RNA转变成dsRNA。


放大效应

在线虫中,小量的dsRNA 能够使大量的靶RNA沉默。 这种现象至少有三种机制:1、Dicer酶将长dsRNA分子切成短的"初级"短RNA(siRNA)(如下图), 因为每一个siRNA具有结合一个同源mRNA的能力,效应的放大水平取决于dsRNA的长度 ,很容易检测到放大10~20倍。2、siRNA在酶作用中,可多次应用,能提供进一步放大。3、 短RNAs可作为靶mRNA的引物,产生后代"次级siRNAs"(靶序列直接扩增),并且这样启动一个RNA诱导的RNA聚合反应。

  


靶依赖的放大效应

这个反应的第一步,mRNA被初级siRNA所识别。假设反应顺序如下: dsRNA被切成短的siRNAs,假定这些从dsRNA转变成ssRNA,接着会发生两个事件。这些siRNAs (可能与蛋白质结合) 它们本身不稳定,并且被降解,除非它们在细胞中识别同源靶mRNA,并且与它结合 。这在线虫中有三个证据:1、在体内RNAi对抗一个标志基因[绿荧光基因(GFP)] 不能够导致可测定的siRNA,除非GFP基因被表达在靶组织;2、在体内仅看到siRNA的反义链,没有有意义链;3、许多RNAi缺陷的突变,在体内不能测定到稳定状态的siRNA,而Dicer酶的活性在体外通过细胞粗提物很容易测定到。显然,这些突变能使siRNA在野生型水平,但不能使它们稳定,可能它们没有达到siRNA与它们的靶序列配对的阶段 。

稳定性提供一个迅速而特异的过滤器,假如无论什么原因产生了dsRNAs ,假如没有相应的能被它们作用而沉默的mRNAs存在, 反应立即消失,因为siRNA是不稳定的。另一方面,假如存在这些siRNA的靶RNA,那么反应会继续。

然后,进入第二步,反义siRNA与靶mRNA结合后,能出现靶序列诱导的扩增。在蠕虫和植物中, 在一个基因中间的一个区域相应的dsRNA诱导的RNA干预(RNAi ),导致靶位点侧siRNA的合成。在蠕虫(而不是植物和果蝇提取物)这个影响显示多极性(仅看到5' 端次级siRNA), 并且这是一个很清楚的距离的影响,被称之为"过度效应"不能进一步延伸到几百个碱基对。可能许多来自起始dsRNA覆盖的区域(称为"初级"siRNA)的siRNA可能同样是次级的和是由于在这个区域内的短的延长反应的产物。过度性RNAi的第二项指标是RNAi直接对抗(转基因)基因融合的表现 ,这个效应可以从一个3'端到一个5'端的区域,并且因此影响到一个5'端区域的没有关系的未融合的基因 。最后,可以通过注射短的反义RNAs来触发有效的RNAi。


扩增需要的聚合酶在不同的组织可能不同。在线虫的胚系,ego-1 基因已被RNAi涉及;它与以前从西红柿中分离的一个RdRP 有同源序列。在线虫的躯体细胞,发现另一个RdRP 类似物:rrf-1。rrf-1 基因的突变导致RNAi的丢失和siRNA显著减少。另一个RdRP同源物的失活有着相反的效应,增强RNAi作用(rrf-3)。rrf-3 基因产物可能有很低的活性,并且可能与rrf-1在相关复合物中竞争。在网柄菌属(Dictyostelium)中,已发现三个RdRP 类似物。它们中一个(rrpA)丢失,导致RNAi消失和测定不到siRNA。

拟南芥的RdRP类似物SDE1/SGS2同样被过度的RNAi所需要。在线虫和植物中过度RNAi显著不同,在植物中,过度效应可出现在3' 端和5'端方向,结果可在3' 端和5'端靶区域发现次级siRNA。 在植物,siRNAs可以针对一个mRNA诱导一个RdRP,触发合成RNA分子的RdRP 活性。

SiRNA的稳定性和过度RNAi的结合导致一个"连锁反应",多个复制周期可以出现。


结束语

我们正在解剖一个保护物种最敏感部分-遗传密码的古老机制。象脊椎动物的免疫系统,这个装置识别分子寄生者,发动起始应答,并且稳定和放大这种应答。尽管细节可能不同,但只要给予RNAi -沉默机器的部分,基因组防御机制将被扩散。就象免疫学知识奠定了免疫治疗的基础,彻底了解基因组免疫系统具有很大可能在直接基因沉默中应用,在实验生物学,甚至在疾病的治疗。


  译自5月17出版的《科学》


‹ 上一主题|下一主题

肝胆相照论坛

GMT+8, 2024-11-23 05:22 , Processed in 0.019859 second(s), 10 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.